Gathering the record
Relay is organizing the evidence and source boundaries.
Informal two-component GH-axis combination label
CJC/IPA is a community label for CJC-1295 no DAC / Mod GRF(1-29) paired with ipamorelin. No verified trial of the combination was located. Published CJC-1295 DAC studies involve a different active moiety and cannot be transferred to this blend.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
CJC/Ipamorelin is a community label for material described as short-acting CJC-1295 without DAC, also called modified GRF(1-29), combined with ipamorelin.
The components are intended to stimulate the growth-hormone system through different upstream signals. A direct study would be needed to determine whether the pairing changes hormone exposure, clinical effects, interactions, or safety.
No verified trial of the exact combination was located. Published CJC-1295 human studies concern the chemically different long-acting DAC form. Ipamorelin's human record is limited and includes intravenous hormone research plus a negative postoperative trial.
The no-DAC component's exact identity, the blend ratio, compatibility, pharmacokinetics, hormone response, repeated-use safety, clinical outcomes, reconstitution, and stability remain unresolved. Evidence from the DAC molecule cannot be transferred because the names look similar.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
No verified primary study administering the exact two-component blend was located; available human records concern separate components or a different CJC-1295 identity.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
The available record consists of separate-component evidence and a documented absence of verified combination trials.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Different upstream receptors provide a rationale, but no direct evidence establishes synergy, compatibility, safety, or clinical benefit.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Long-acting CJC-1295 DAC is a different active moiety and cannot support the no-DAC component. Separate ipamorelin research cannot establish combination benefit, compatibility, safety, or handling. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
None for the combination, and no controlled human no-DAC CJC study was located. Ipamorelin has a 48-person intravenous hormone study; its 117-person intravenous Phase 2 trial did not demonstrate significant efficacy. CJC-1295 DAC findings concern a different active moiety.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
The no-DAC CJC salt and formulation, component ratio, compatibility, combined pharmacokinetics and GH/IGF-1 response, interactions, immunogenicity, repeated-use safety, and meaningful clinical outcomes.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This record uses the common shorthand for the short-acting, non-DAC CJC component paired with ipamorelin. It does not include long-acting CJC-1295 DAC.
PubMed and ClinicalTrials.gov searches through July 25, 2026 did not identify a controlled or registered study administering the exact combination.
FDA's ipamorelin review records a subject-matter expert's description of the practice, not a controlled comparison.
FDA distinguishes DAC and non-DAC active moieties. Located human CJC pharmacology appears to involve the long-acting DAC form.
The no-DAC CJC component is a GHRH analogue, while ipamorelin activates GHSR1a. Both pathways can affect pituitary GH release and downstream IGF-1 signaling.
The strongest located human evidence concerns intravenous ipamorelin or the different CJC-1295 DAC active moiety.
Separate ingredient observations cannot show what happens when the materials are combined in one preparation or used concurrently.
Component research used different active moieties, routes, and protocols. Those records cannot be merged into consumer instructions.
Mechanisms
The no-DAC CJC component is a short-acting GHRH analogue, while ipamorelin is a GHSR1a agonist. The distinct upstream receptors are intended to converge on pituitary GH release and downstream IGF-1 signaling, creating mechanistic overlap without demonstrating useful synergy. Located CJC human pharmacology appears to involve the different long-acting DAC active moiety, while controlled ipamorelin human studies used intravenous administration. No blend pharmacokinetic, compatibility, stability, interaction, dose-response, safety, or efficacy study was located.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Multicenter, randomized, double-blind, placebo-controlled study after bowel resection
Hospitalized adults after small- or large-bowel resection
The primary endpoint was not significantly shorter with ipamorelin, and key secondary outcomes did not demonstrate significant efficacy.
Study administration: Intravenous ipamorelin under the study protocol or placebo
Limitations: This condition-specific intravenous study did not administer CJC-1295 no DAC and cannot establish outpatient use or a CJC/Ipamorelin blend effect.
Two randomized, double-blind, placebo-controlled, ascending-dose studies
Healthy adults aged 21–61 years
CJC-1295 DAC produced sustained GH and IGF-1 changes in this small pharmacology program.
Study administration: Subcutaneous CJC-1295 DAC of unspecified salt; this is a different active moiety and not a blend protocol
Limitations: This study used a different CJC active moiety—the long-acting DAC form—and did not administer ipamorelin. Its findings must not be assigned to the no-DAC/Mod GRF(1-29) component in this blend.
Randomized, placebo-controlled, intravenous dose-escalation study
Healthy adult men
Ipamorelin produced a concentration-dependent short-term GH response.
Study administration: Fifteen-minute intravenous ipamorelin infusions across five research-dose groups or placebo
Limitations: This intravenous study did not administer CJC-1295 no DAC. It provides no subcutaneous or combination pharmacokinetic, safety, compatibility, or outcome evidence.
Randomized, double-blind, placebo-controlled CJC-1295 trial
Adults with HIV-associated visceral obesity
The trial was terminated and did not post results.
Study administration: Weekly subcutaneous CJC-1295 or placebo under the registered protocol
Limitations: The registration does not clearly establish applicability to the no-DAC blend component, posted no results, and did not test ipamorelin, compatibility, ratio, or combined safety.
Safety snapshot
No blend-specific compatibility, stability, pharmacokinetic, interaction, or safety study was located.
No direct evidenceUnknown evidence is not a finding of compatibility or incompatibility.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNo FDA-approved CJC-1295 no DAC/ipamorelin fixed-combination product was located. Ingredient-level advisory actions do not approve the blend. Growth-hormone-releasing factors and secretagogues are prohibited in sport under WADA S2. The no-DAC CJC salt and formulation, component ratio, compatibility, combined pharmacokinetics and GH/IGF-1 response, interactions, immunogenicity, repeated-use safety, and meaningful clinical outcomes.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-25
2026-07-25
2026-01-01
2024-11-15
2024-09-27
2014-10-21 · PMID 25331030 · NCT00672074 · DOI 10.1007/s00384-014-2030-8
2006-03-01 · PMID 16352683 · DOI 10.1210/jc.2005-1536
2005-12-23 · NCT00267527
1999-09-01 · PMID 10496658 · DOI 10.1023/A:1018955126402